Inside the efforts to rescue a rare disease gene therapy
A parent’s worst nightmare is being told their child has been diagnosed with a rare disease. But being unable to…
17 Jul 2024
Drug development costs predicted to soar as BIOSECURE Act gains momentum
Since its introduction in January, the BIOSECURE Act has sent shockwaves across the pharmaceutical sector. Although the Act does not propose a blanket prohibition, its definition of prohibiting federal funding…
12 Jul 2024
Explainer: Labour has been elected in the UK – now what?
Following the announcement of the UK Labour Party’s near-landslide victory on 5 July, healthcare workers and life science investors have been tentatively awaiting the first moves and measures of a…
04 Jul 2024
Does H5N1 avian influenza have pandemic potential?
The global medical community is beginning to mobilise in response to the growing threat of pandemic posed by the H5N1 strain of avian influenza. On 2 July, the US government…
03 Jul 2024
Left in limbo: When pharma halts rare disease research
The development of drugs and gene therapies for rare diseases is costly. It requires significant investments in advanced technology, clinical trials, and regulatory approvals. But what happens when the development…
01 Jul 2024
UK’s pharma sector votes for post-Brexit clarity under new government
Whilst Prime Minister Rishi Sunak and Labour Party leader Keir Starmer, centre attention on migration and tax policies, the UK healthcare industry awaits a new government that will tackle Brexit’s…
27 Jun 2024
Capturing the genAI boom for drug development
With every week that passes, it seems a pharmaceutical company has tied a new deal with an artificial intelligence (AI) provider. The US Food and Drug Administration (FDA) is approving…